InfoCons Consumer Protection informs you – Anagrelide Viatris – Package Leaflet

Anagrelide Viatris – Package Leaflet: InfoCons – Consumer Protection presents, in an accessible format, the official package leaflet of the medicine Anagrelide Viatris, as authorised in the European Union and published in the Union Register of medicinal products.

📋 Anagrelide Viatris – at a glance
Active substance anagrelide
ATC code L01XX35
EU authorisation number EU/1/17/1256
Marketing Authorisation Holder Viatris Limited
Therapeutic indication Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk…
Last Commission decision 2024-04-09

Before anything else

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have further questions, ask your doctor or pharmacist.
  • This medicine has been prescrib ed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects , talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See se ction 4.

ℹ️ 1. What Anagrelide Viatris is and what it is used for

Anagrelide Viatris contains the active substance, anagrelide. Anagrelide is a medicine which interferes with the development of platelets. It reduces the numbe r of platelets produced by the bone marrow, which results in a decrease in the platelet count in the blood towards a more normal level. For this reason , it is used to treat patients with essential thrombocythaemia.

Essential thrombocythaemia is a conditio n which occurs when the bone marrow produces too many of the blood cells known as platelets. Large numbers of platelets in the blood can cause serious problems with blood circulation and clotting.

⚠️ 2. What you need to know before you take Anagrelide Viatris

Do not take Anagrelide Viatris

  • If you are allergic to anagrelide or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may be recognised as a rash, itching, swollen face or lips, or shortness of breath;
  • If you have moderate or severe liver problems ;
  • If you have moderate or severe kidney problems.

Warnings and precautions

Talk to your doctor before taking Anagrelide Viatris :

  • If you have or think you might have a problem with your heart;
  • If you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), or you are taking other medicines that result in abnormal ECG changes or if you have low levels of electrolytes , e.g., potassium, magnesium or calcium (see section “Other medicines and Anagrelide Viatris ”);
  • If you have any problems with your liver or kidneys.

In combination with acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin), there is an increased risk of major haemorrhages (bleeding) (see section “Other medicines and Anagrelide Viatris ”).

While taking Anagrelide Viatris , you should take the exact dose prescribed by your doctor. Do not stop taking the medicine without first talking to your doctor. Do not abruptly stop taking this medicine without consulting your doctor. Abrupt withdrawal of medicine may lead to increased risk of stroke.

Signs and symptoms of stroke may include sudden numbness or weakness in the face, a rm, or leg, especially on one side of the body, sudden confusion, trouble speaking, or difficulty understanding speech, sudden trouble seeing in one or both eyes, sudden trouble walking, dizziness, loss of balance, or lack of coordination and sudden severe headache with no known cause. Please seek immediate medical help.

Children and adolescents

There is limited information on the use of anagrelide in children and adolescents and therefore this medicine should be used with caution.

Other medicines and Anagrelide Viatris

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.

Tell your doctor if you are taking any of the following medicines:

  • Medicines that can alter your heart rhythm , e.g., sotalol, amiodarone;
  • Fluvoxamine, used to treat depression;
  • Certain types of antibiotic, such as enoxacin, used to treat infections;
  • Theophylline, used to treat severe asthma and breathing problems;
  • Medicines used to treat heart disorders, for exam ple, milrinone, enoximone, amrinone, olprinone and cilostazol;
  • Acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin);
  • Other medicines used to treat con ditions affecting the platelets in your blood, e.g. , clopidogrel;
  • Omeprazole, used to reduce the amount of acid produced in the stomach;
  • Oral contraceptives: If you experience bad diarrhoea whilst taking this medicine, it may reduce how well the oral contraceptive works and use of an extra method of contraception is recommended (e.g. , condom). See the instructions in the patient leaflet of the contraceptive pill you are taking.

Anagrelide or these medicines may not work properly if taken together.

If you are not sure, speak to your doctor or pharmacist for advice.

Pregnancy and breast -feeding Tell your doctor if you are pregnant or are planning to become pregnant. Anagrelide Viatris should not be taken by pregnant women. Women who are at risk of beco ming pregnant should make sure that they are using effective contraception when taking anagrelide. Speak to your doctor if you need advice with contraception.

Tell your doctor if you are breast -feeding or if you are planning to breast -feed your baby. Anagrelide Viatris should not be taken while breast -feeding. You must stop breast -feeding if you are taking Anagrelide Viatris .

Driving and using machines

Dizziness has been reported by some patients taking anagrelide. Do not drive or use machines if you feel dizzy.

Anagrelide Viatris contains lactose and sodium

This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine contains less than 1mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium -free’.

💊 3. How to take Anagrelide Viatris

Always take Anagrelide Viatris exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The amount of anagrelide that people take can be different, and this depends on your condition. Your doctor will prescribe the best dose for you.

The usual st arting dose of anagrelide is 1 mg. You take this dose as one capsule of 0.5 mg twice a day, for at least a week. After this time, your doctor may either increase or decrease the number of capsules that you take to find the dose best suited to you and which treats your condition most effectively.

Your capsules should be swallowed whole with a glass of water. Do not crush the capsules or dilute the contents in a liquid. You can take the capsules with food or after a meal or on an empty stomach. It is best to take the capsule(s) at the same time every day.

Do not take more or less capsules than your doctor has recommended. Do not stop taking the

medicine without first talking to your doctor. You should not suddenly stop taking this medicine on your own.

Your doctor will ask you to have blood tests at regular intervals to check that your medicine is working effectively and that yo ur liver and kidneys are working well.

If you take more Anagrelide Viatris than you should

If you take more Anagrelide Viatris than you should or if someone else has taken your medicine, tell a doctor or pharmacist immediately. Show them the pack of Anagrelide Viatris .

If you forget to take Anagrelide Viatris

Take your capsules as soon as you remember. Take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose.

❗ 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. If you are worried, speak to your doctor.

Serious side effects

Uncommon: Heart failure (signs include shortness of breath, chest pain, swelling of the legs due to fluid build -up), severe problem with the rate or rhythm of the heartbeat (ventricular tachycardia, supraventricular tachycardia or atrial fibrillat ion), inflammation of the pancreas which causes severe abdominal and back pain (pancreatitis), vomiting blood or passing bloody or black stools, severe reduction in blood cells which can cause weakness, bruising, bleeding or infections (pancytopenia), increased pressure in the lung arteries (signs include shortness of breath , swelling in legs or ankles and lips and skin can turn bluish colour).

Rare: Kidney failure (when you pass little or no urine), heart attack.

If you notice any of thes e side effects, c ontact your doctor immediately .

Other possible side effects

Very common side effects (may affect more than 1 in 10 people )

Headache.

Common side effects (may affect up to 1 in 10 people )

Dizziness, tiredness, rapid heartbeat, irregular or strong heartbeat (palpitations), feeling sick (nausea), diarrhoea, stomach pain, wind, being sick (vomiting), reduction in red blood cell count (anaemia), fluid retention or rash.

Uncommon side effects (may affect up to 1 in 100 people )

A feeling of weakness or feeling unwell, high blood pressure, irregular heartbeat, fainting, chills or fever, indigestion, loss of appetite, constipation, bruising, bleeding, swelling (oedema), weight loss, muscle aches, painful joints, back pain, decreased or loss of feeling or sensation such as numbness, especially in the skin, abnormal feeling or sensation such as tingling and ‘pins and needles’, sleeplessness, depression, confusion, nervousness, dry mouth, loss of memory, breathlessness, nosebleed, serious lung infe ction with fever, shortness of breath, cough, phlegm; hair loss, skin itching or discolouration, impotence, chest pain, reduction in blood platelets, which increases the risk of bleeding or bruising (thrombocytopenia), accumulation of fluid around the lung s or an increase in liver enzymes. Your doctor may do a blood test which may show an increase in your liver enzymes.

Rare side effects (may affect up to 1 in 1,000 people )

Bleeding gums, weight gain, severe chest pain (angina pectoris), heart muscle dise ase, (signs include fatigue, chest pain and palpitations), enlarged heart, accumulation of fluid around the heart, painful spasm of the blood vessels on the heart (while resting, usually at night or early morning) (Prinzmetal angina), loss of coordination, difficulty in speaking, dry skin, migraine, visual disturbances or double vision, ringing in the ears, dizziness on standing up (especially when getting up from a sitting or lying position), increased need to pass water at night, pain, ‘flu -like’ symptoms , sleepiness, widening of blood vessels, inflammation of the large bowel (signs include: diarrhoea, usually with blood and mucus, stomach pain, fever), inflammation of the stomach (signs include: pain, nausea, vomiting), area of abnormal density in the lun g, increased creatinine level in blood tests, which may be a sign of kidney problems.

The following side effects have been reported but it is not known exactly how often they occur:

  • Potentially life -threatening, irregular heartbeat ( Torsade de pointes);
  • Inflammation of the liver, symptoms include nausea, vomiting, itching, yellowing of the skin and eyes, discoloration of stool and urine (hepatitis);
  • Lung inflammation (signs include fever, coughing, difficulty breathing, wheezing; which causes scaring of th e lungs) (allergic alveolitis, including interstitial lung disease, pneumonitis);
  • Inflammation of the kidneys (tubulointerstitial nephritis).
  • Stroke (see section 2).

Reporting of side effects

If you get any side effects , talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects , you can help provide more information on the safety of this medicine.

🌡️ 5. How to store Anagrelide Viatris

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP.

The expiry date refers to the last day of that month.

Store in the original package in ord er to protect from moisture .

This medicinal product does not require any special temperature storage conditions.

If your doctor stops your medicine, do not keep any leftover capsules unless your doctor tells you to.

Do not throw away any medicines via was tewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

📦 6. Contents of the pack and other information

What Anagrelide Viatris contains

The active substance is anagrelide. Each capsule contains anagrelide hydrochloride monohydrate equivalent to 1 mg anagrelide.

The other ingredients are lactose, croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin , titanium dioxide (E171) and iron oxide black (E172). See section 2 ‘Anagrelide Viatris contains lactose and sodium ’.

What Anagrelide Viatris looks like and contents o f the pack Anagrelide Viatris 1 mg hard capsules have a grey body and cap. The capsule is filled with a white to off-white powder.

The capsule size is approximately 14.3 x 5.3 mm.

Anagrelide Viatris is available in plastic bottles of 30 ml or 75 ml with a tamper evident, child -resistant closure and a desiccant . Each bottle contain s 100 hard capsules.

Marketing Authorisation Holder

Viatris Limited Damastown Industrial Park Mulhuddart, Dublin 15 DUBLIN Ireland

Manufacturer

Synthon Hispania SL C/ Castelló no1 POL. Las Salinas Sant Boi de Llobregat 08830 Barcelona Spain Synthon BV Microweg 22 6545 CM Nijmegen The Netherlands For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België /Belgique/Belgien Viatris Tél/Tel: + 32 (0)2 658 61 00 Lietuva Viatris UAB Tel: +370 5 205 1288 България Майлан ЕООД Тел: +359 2 44 55 400 Luxembourg/Luxemburg Viatris Tél/Tel: + 32 (0)2 658 61 00 (Belgique/Belgien ) Česká republika Viatris CZ s.r.o.

Tel: + 420 222 004 400 Magyarország Viatris Healthcare Kft.

Tel.: + 36 1 465 2100 Danmark Viatris ApS Tlf: +45 28 11 69 32 Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 74 Deutschland Viatris Healthcare GmbH Tel: +49 800 0700 800 Nederland Mylan BV Tel: + 31 (0)20 426 3300 Eesti Viatris OÜ Tel: + 372 6363 052 Norge Viatris AS Tlf: + 47 66 75 33 00 Ελλάδα Viatris Hellas Ltd Τηλ: +30 210 0 100 002 Österreich Arcana Arzneimittel GmbH Tel: +43 1 416 2418 España Viatris Pharmaceuticals, S.L .

Tel: + 34 900 102 712 Polska Viatris Healthcare Sp. z o.o.

Tel.: + 48 22 546 64 00 France Viatris Santé Tél: +33 4 37 25 75 00 Portugal Mylan, Lda.

Tel: + 351 214 127 200 Hrvatska Viatris Hrvatska d.o.o.

Tel: +385 1 23 50 599 România BGP Products SRL Tel: +40 372 579 000 Ireland Mylan Ireland Limited Tel: +353 1 8711600 Slovenija Viatris d.o.o.

Tel: + 386 1 23 63 180 Ísland Icepharma hf .

Sími: +354 540 8000 Slovenská republika Viatris Slovakia s.r.o.

Tel: +421 2 32 199 100 Italia Viatris Italia S.r.l.

Tel: + 39 (0) 2 612 46921 Suomi/Finland Viatris Oy Puh/Tel : +358 20 720 9555 Κύπρος GPA Pharmaceuticals Ltd Τηλ: +357 22863100 Sverige Viatris AB Tel: +46 (0)8 630 19 00 Latvija Viatris SIA Tel: +371 676 055 80 United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited Tel: +353 18711600

This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu . There are also links to other websites about rare diseases an d treatment s.

📄 Package Leaflet – official source

This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Anagrelide Viatris (PDF, ec.europa.eu).

You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/17/1256).

⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.

Other blog posts

keyboard_arrow_up